Company
Beijing Biotech
Beijing Biotech has 6 drugs tracked on RxWires: 4 in Phase 1/2, 2 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| EB-DT-CAR-NK | Phase 1/2 | Advanced Gastric Adenocarcinoma |
| EBNK-1822H2 dual-target CLDN18.2/HER2 CAR-NK cells | Phase 1/2 | Recurrent or Metastatic Esophageal Adenocarcinoma |
| EB-DTNB-NK | Phase 1/2 | Relapsed Neuroblastoma |
| EB-DART-NK01 (DLL3/CD56 CAR-NK cells) | Phase 1/2 | Small Cell Lung Cancer (SCLC) |
| Dual-target CAR-NK cells | Phase 1 | Malignant Glioma |
| EB-DT-NK-UC101 | Phase 1 | Bladder Cancer |
Latest
No recent events.
Follow Beijing Biotech on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.